Item 7.01. Regulation FD Disclosure.

On January 7, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria ("PNH"). A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.    Description

                 Press release dated January 7, 2022 entitled "BioCryst Begins
  99.1         Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as
               Oral Monotherapy for Patients with PNH"

104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses